While the stimulation of angiotensin receptor 1 (AT1R) has been suggested to cause cognitive impairment, neuronal cell death and neuroinflammation (for review see [1,2]), the AT1R blockers (ARBs) were shown to blunt these effects when administered systemically or intranasally in rodent models of AD [3,4,5,6]. This evidence concerns the gene AGTR1 and Alzheimer disease.